Scribe Therapeutics Inc. (SCTX) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Scribe Therapeutics Inc. (SCTX) closed at USD 20.77 on 2026-10-14, a change of +9.5 % over the past year, with a market capitalization of USD 392.26M.

Scribe Therapeutics Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Scribe Therapeutics Inc. key figures

Previous close

USD 20.77 (2026-10-14)

1-year change

+9.5 %

Market cap

USD 392.26M

Enterprise value

USD 512.88M

P/E ratio (trailing)

-4.98

P/E ratio (forward)

-5.73

EPS (trailing)

-4.16

EPS (forward)

-3.62

PEG ratio

n/a

Price to book

-0.31

Revenue growth

-60.8 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

5.68

Employees

82

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Scribe Therapeutics Inc.

Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States. The company offers STX-1150 designed to be a single-course in vivo epigenetic silencing treatment targeting the PCSK9 gene; STX-1200 is CRISPR-based gene editing program that aims to offer a permanent solution for patients with elevated Lp(a); and STX-1400 is designed to target and remove the transcriptional start site of the APOC3 gene and strongly reduce mRNA expression. It uses CRISPR-based platforms, such as ELXR, designed for precise, durable epigenetic silencing of genes without changing the underlying DNA sequence; and XE, designed to support specific and efficient gene editing. The company was incorporated in 2017 and is headquartered in Alameda, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Scribe Therapeutics Inc. and compare it with other stocks.